Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06110130 · ClinicalTrials.gov registry record · Phase 4
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
A Phase 4 study of Chronic Kidney Diseases, sponsored by Washington D.C. Veterans Affairs Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06110130 is a Phase 4 study of Chronic Kidney Diseases that is actively recruiting participants, run by Washington D.C. Veterans Affairs Medical Center. The registered enrollment target is 60 participants, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06110130, a Phase 4 study of Chronic Kidney Diseases, is actively recruiting participants, sponsored by Washington D.C. Veterans Affairs Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein. Secondary Objective: 1. Correlate changes in exosome-based podocyte specific proteins with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR. 2. Correlate systemic inflammatory markers (focusing on vascular and endothelial function) that are already established such as interleukins (IL1, IL6, IL-12) , hs-CRP and arterial stiffness measures with urine exosome-based podocyte protein estimation. 3. Correlate urine podocyte-specific protein markers with APOL1 mRNA expression levels in blood mononuclear cells (MNC)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Empagliflozin 10 MG
Study Locations (1)
District of Columbia
- Washington DC Veterans Affairs Medical Center (688) - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-02-02 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06110130
The ClinicalTrials.gov registry entry for NCT06110130 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (86% lower). The listed sponsor is Washington D.C. Veterans Affairs Medical Center, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06110130 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06110130 about?
NCT06110130 is a clinical study titled "Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD". Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, p...
What is the current status of trial NCT06110130?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2024-02-02. Estimated completion is 2028-12-01.
What conditions does trial NCT06110130 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases.
What interventions are being tested in trial NCT06110130?
The interventions under investigation include: Placebo (DRUG), Empagliflozin 10 MG (DRUG).
Who is sponsoring clinical trial NCT06110130?
This trial is sponsored by Washington D.C. Veterans Affairs Medical Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06110130 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Iron in Children With Chronic Kidney Disease
RECRUITING · Phase 4
-
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
RECRUITING · Phase 4
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
Immunogenicity of HPV Vaccine in Transplant Recipients.
ACTIVE NOT RECRUITING · Phase 4
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.